고혈압 약물과 중성약의 병용투여 연구현황 고찰

This study aimed to provide current information on combined use of chinese patent medicines (CPM) and antihypertensive agents. Clinical articles were searched with China National Knowledge Infrastructure (CNKI). Primary keywords were 81 antihypertensive agents permitted in Korea. Secondary keywords were 59 chinese patent medicines which have effect on lowering blood pressure. Search queries made of combined keywords were processed. Searched articles were analyzed as study designs, diagnostic standards, blood pressure measurements, adverse events and interactions. Sixty-one articles of randomized trials (n=43), non-randomized trials (n=3) and case studies (n=15) were selected. Total 42 pairs among 15 antihypertensive agents and 17 chinese patent medicines were analyzed. Seven global or domestic guidelines were adopted to diagnose hypertension and 9 tools were used to assess effectiveness. Severe adverse events were reported from hydrochlorothiazide with zhenju jiangya-pian (珍菊降压片) or jiangya bifeng-pian (降压避风片), captopril with songling xuemaikang-jiaonang (松龄血脉康胶囊) and nifedipine with fubang danshen-diwan (复方丹参滴丸). Combined use of antihypertensive drugs and chinese patent medicines can cause various clinical conditions. Healthcare professionals also patients and caregivers should be informed of herb-drug interaction risk and safety.